ChemoCentryx ContactKeep Me PostedSite Map
Medicines in MotionChemoCentryx is a clinical stage focused pharmaceutical company creating small molecule medicines for autoimmune diseases, inflammatory disorders and oncology.
Announcement
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN™ ) in Crohn's Disease
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 Drug Represents Potential New Approach for the Treatment of Inflammatory Disease
ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
  More News >
GET MORE information about ChemoCentryx's products. LEARN ABOUT chemokines and diseases. FIND OUT about clinical trials of Traficet-EN™ for IBD.
GET MORE information about ChemoCentryx's products. LEARN ABOUT chemokines and diseases. FIND OUT about clinical trials of Traficet-EN for IBD.

© 2008 ChemoCentryx, Inc. Legal | Site User's Guide